Hapten-carrier conjugates and uses thereof

Patent Citations (92)

Non-Patent Literature (453)

• Fehr et al. PNAS 95: 9477-9481, 1998.Examiner
• Abad, A., et al., “Comparison of a Monoclonal Antibody-Based Enzyme-Linked Immunosorbent Assay and Gas Chromatography for the Determination of Nicotine in Cigarette Smoke Condensates,” Anal Chem. 65:3227-3231, American Chemical Society (1993).Applicant
• Bonese, K.F., et al., “Changes in heroin self-administration by a rhesus monkey after morphine immunisation,” Nature 252:708-710, Nature Publishing Group (1974).Applicant
• Byrnes-Blake, K.A., et al., “Generation of anti-(+)methamphetamine antibodies is not impeded by (+)methamphetamine administration during active immunization of rats,” Int. Immunopharmacol. 1:329-338, Elsevier (Feb. 2001).Applicant
• Carpino, L.A., “1-Hydroxy-7-azabenzotriazole. An Efficient Peptide Coupling Additive,” J. Am. Chem. Soc. 115:4397-4398, American Chemical Society (1993).Applicant
• Carrera, M.R., et al., “Suppression of psychoactive effects of cocaine by active immunization,” Nature 378:727-730, Nature Publishing Group (1995).Applicant
• Carrera, M.R., et al., “Cocaine vaccines: Antibody protection against relapse in a rat model,” Proc. NatI. Acad. Sci. USA 97:6202-6206, National Academy Press (2000).Applicant
• Carrera, M.R., et al., “A second-generation vaccine protects against the psychoactive effects of cocaine,” Proc. Natl. Acad. Sci. USA 98:1988-1992, National Academy Press (Feb. 2001).Applicant
• Castaldi, G., et aI., “Tartaric Acid, an Efficient Chiral Auxiliary: New Asymmetric Synthesis of 2-Alkyl-2-arylacetic Acids,” J. Org. Chem. 52:3018-3027, American Chemical Society (1987).Applicant
• Castro, A., and Prieto, I., “Nicotine antibody production: comparison of two nicotine conjugates in different animal species,” Biochem. Biophys. Res. Commun. 67:583-589, Academic Press (1975).Applicant
• Castro, A., et al, “Nicotine Antibodies: Comparison of Ligand Specificities of Antibodies Produced against Two Nicotine Conjugates,” Eur. J. Biochem. 104:331-340, Blackwell Publishing (1990).Applicant
• Cohen, C., et al., “SR141716, a central cannabinoid (CB2) receptor antagonist, blocks the motivational and dopamine-releasing effects of nicotine in rats,” Behav. Pharmacol. 13:451-463, Lippincott Williams & Wilkins (2002).Applicant
• da Costa, C.L., et al., “Stopping Smoking: A prospective, Randomized, Double-Blind Study Comparing Nortriptyline to Placebo,” Chest 122:403-408, The American College of Chest Physicians (Aug. 2002).Applicant
• Fox, B.S., et aI., “Efficacy of a therapeutic cocaine vaccine in rodent models,” Nat. Med. 2:1129-1132, Nature Publishing Group (1996).Applicant
• Hardin, J.S., et al., “Pharmacodynamics of a Monoclonal Antiphencyclidine Fab with Broad Selectivity for Phencyclidine-Like Drugs,” J. Pharmacol. Exp. Ther. 285:1113-1122, The American Society for Pharmacology and Experimental Therapeutics (1998).Applicant
• Hieda, Y., et al., “Vaccination against nicotine during continued nicotine administration in rats: immunogenicity of the vaccine and effects on nicotine distribution to brain,” Int. J. Immunopharmacol. 22:809-819, Elsevier Science Ltd. (2000).Applicant
• Hieda, Y., et al., “Active Immunization Alters the Plasma Nicotine Concentration in Rats,” J. Pharmacol. Exp. Ther. 283:1076-1081, The American Society for Pharmacology and Experimental Therapeutics (1997).Applicant
• Hieda, Y., et al., “Immunization of rats reduces nicotine distribution to brain,” Psychopharmacology (Berl) 143:150-157, Springer-Verlag (1999).Applicant
• Hodge, L.M., et al., “Immunoglobulin A (IgA) Responses and IgE-Associated Inflammation along the Respiratory Tract after Mucosal but Not Systemic Immunization,” Infect. Immun. 69:2328-2338, American Society for Microbiology (Apr. 2001).Applicant
• Isomura, S., et al., “An Immunotherapeutic Program for the Treatment of Nicotine Addiction: Hapten Design and Synthesis,” J. Org. .Chem. 66:4115-4121, American Chemical Society (Jun. 2001).Applicant
• Jorenby, D.E., et al., “A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation,” N. Engl. J. Med. 340:685-691, Massachusetts Medical Society (1999).Applicant
• Joseph, A.M., et al., “Lack of Efficacy of Transdermal Nicotine in Smoking Cessation,” N. EngI. J. Med. 341:1157-1158, Massachusetts Medical Society (1999).Applicant
• Killian, A., et al., “Effects of Passive Immunization Against Morphine on Heroin Self-Administration,” Pharmacol. Biochem. Behav. 9:347-352, ANKHO International Inc. (1978).Applicant
• Klovins, J., et al., “Nucleotide sequence of a ssRNA phage from Acinetobacter: kinship to coliphages,” J. Gen. Virol. 83:1523-1533, Cambridge University Press (Jun. 2002).Applicant
• Langone, J.J. & VanVunakis, H., “Radioimmunoassay of Nicotine, Cotinine, and γ-(3-Pyridyl)-γ-oxo-N-methylbutyramide,” Methods Enzymol. 84:628-640, Academic Press (1982).Applicant
• Langone, J.J., et al., “Nicotine and Its Metabolites. Radioimmunoassays for Nicotine and Cotinine,” Biochemistry 12:5025-5030, American Chemical Society (1973).Applicant
• Malin, D.H., et al., “Passive immunization against nicotine prevents nicotine alleviation of nicotine abstinence syndrome,” Pharmacol. Biochem. Behav., 68:87-92, Elsevier Science (Jan. 2001).Applicant
• Matsushita, H., et al., “Conjugate of bovine serum albumin with nicotinem,” Biochem. Biophys. Res. Commun. 57:1006-1010, Academic Press, Inc. (1974).Applicant
• Meijler, M.M., et al., “A New Strategy for Improved Nicotine Vaccines Using Conformationally Constrained Haptens,” J. Am. Chem. Soc. 125:7164-7165, American Chemical Society (Jun. 2003).Applicant
• Musso, D.L., et al., “Synthesis and Evaluation of the Antidepressant Activity of the Enantiomers of Bupropion,” Chirality 5:495-500, Wiley-Liss, Inc. (1993).Applicant
• Noguchi, M., et al., “Conjugate of nicotine and cotinine to bovine serum albumin,” Biochem. Biophys. Res. Commun. 83:83-86, Academic Press, Inc. (1978).Applicant
• Pentel, P.R., et al., “A Nicotine Conjugate Vaccine Reduces Nicotine Distribution to Brain and Attenuates Its Behavioral and Cardiovascular Effects in Rats,” Pharmacol. Biochem. Behav. 65:191-198, Elsevier Science (2000).Applicant
• Proksch, J.W., et al., “Anti-Phencyclidine Monoclonal Antibodies Provide Long-Term Reductions in Brain Phencyclidine Concentrations during Chronic Phencyclidine Administration in Rats,” J. Pharmacol. Exp. Ther. 292:831-837, The American Society for Pharmacology and Experimental Therapeutics (2000).Applicant
• Simecka, J.W., et al., “Mucosally Induced Immunoglobulin E-Associated Inflammation in the Respiratory tract,” Infect. Immun. 68:672-679, American Society for Microbiology (2000).Applicant
• “Sindbis Expression System,” Version E, Invitrogen Corporation, Carlsbad, CA, Catalog No. K750-1 (Apr. 2002).Applicant
• Stoll, E., et al., “Revised Amino Acid Sequence of Qβ Coat Protein between Positions 1 and 60,” J. Biol. Chem. 252:990-993, The American Society for Biochemistry and Molecular Biology (1977).Applicant
• Yamamoto, S., et al., “A nontoxic mutant of cholera toxin elicits Th2-type responses for enhanced mucosal immunity,” Proc. Natl. Acad. Sci. USA 94:5267-5272, National Academy Press (1997).Applicant
• NCBI Entrez, GenBank Report, Accession No. NP_695026, from Inokuchi et al. (Jul. 2003).Applicant
• Dialog File 351, Accession No. 8799418, Derwent WPI English language abstract for WO 92/03163 (Document AO5).Applicant
• Dialog File 351, Accession No. 9721628, Derwent WPI English language abstract for EP 0 576 357 (Document AL6).Applicant
• Dialog File 351, Accession No. 12999043, Derwent WPI English language abstract for WO 00/00462 (Document AM7).Applicant
• Dialog File 351, Accession No. 15395298, Derwent WPI English language abstract for WO 03/040105 (Document AL9).Applicant
• Jegerlehner, A., et al., “A molecular assembly system that renders antigens of choice highly repetitive for induction of protective B cell responses,” Vaccine 20:3104-3112, Elsevier Science, Ltd. (Aug. 2002).Applicant
• The Biology of Animal Viruses, 2nd ed., Fenner, F., et al., eds., Academic Press, New York, NY, pp. 117-119 (1974).Applicant
• NCBI Entrez, PubMed Abstract, PMID: 2205968, Diallo, A., et al., “Morbillivirus group: genome organization and proteins,” Vet. Microbiol. 23:155-163 (1990).Applicant
• Dialog File 351, Accession No. 10300677, Derwent WPI English language abstract for EP 0 656 354 B1 (Document AM9).Applicant
• Abraham, J.M., et al., “An invertible element of DNA controls phase variation of type I fimbriae of Escherichia coli,” Proc. Natl. Acad. Sci. USA 82:5724-5727, National Academy Press (1985).Applicant
• Abraham, S.N., et al., “Glycerol-Induced Unraveling of the Tight Helical Conformation of Escherichia coli Type 1 Fimbriae,” J. Bacteriol. 174:5145-5148, American Society for Microbiology (1992).Applicant
• Adhin, M.R., et al., “Nucleotide Sequence from the ssRNA Bacteriophage JP34 Resolves the Discrepancy between Serological and Biophysical Classification,” Virology 170:238-242, Academic Press, Inc. (1989).Applicant
• Aguzzi, A., “Prion diseases, blood and the immune system: concerns and reality,” Haematologica 85:3-10, Il Pensiero Scientifico Editore (Jan. 2000).Applicant
• Ansel, K.M., et al., “In Vivo-activated CD4 T Cells Upregulate CXC Chemokine Receptor 5 and Reprogram Their Response to Lymphoid Chemokines,” J. Exp. Med. 190:1123-1134, The Rockefeller University Press (1999).Applicant
• Ansel, K.M. et al., “A chemokine-driven positive feedback loop organizes lymphoid follicles,” Nature 406:309-314, Nature Publishing Group (Jul. 2000).Applicant
• Antonysamy, M.A., et al., “Evidence for a Role of IL-17 in Organ Allograft Rejection: IL-17 Promotes the Functional Differentiation of Dendritic Cell Progenitors,” J. Immunol. 162:577-584, The American Association of Immunologists (1999).Applicant
• Arenberg, D.A., et al., “The murine CC chemokine, 6C-kine, inhibits tumor growth and angiogenesis in a human lung cancer SCID mouse model,” Cancer lmmunol. Immunother. 49:587-592, Springer-Verlag (Jan. 2001).Applicant
• Arnon, R., et al., “A mimotope peptide-based vaccine against Schistosoma mansoni: synthesis and characterization,” Immunology 101:555-562, Blackwell Science, Ltd. (Dec. 2000).Applicant
• Bachmann, M.F., and Zinkernagel, R.M., “The influence of virus structure on antibody responses and virus serotype formation,” Immunol. Today 17:553-558, Elsevier Science, Ltd. (1996).Applicant
• Bachmann, M.F., and Zinkernagel, R.M., “Neutralizing Antiviral B Cell Responses,” Annu. Rev. Immunol. 15:235-270, Annual Reviews, Inc. (1997).Applicant
• Bachmann, M.F., et al., “TRANCE, a Tumor Necrosis Factor Family Member Critical for CD40 Ligand-independent T Helper Cell Activation,” J. Exp. Med. 189:1025-1031, The Rockefeller University Press (1999).Applicant
• Banerjee, R.R., and Lazar, M.A., “Dimerization of Resistin and Resistin-like Molecules Is Determined by a Single Cysteine,” J. Biol. Chem. 276:25970-25973, The American Society for Biochemistry and Molecular Biology, Inc. (Jul. 2001).Applicant
• Bard, F. et al., “Peripherally administered antibodies against amyloid β-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease,” Nat. Med. 6:916-919, Nature Publishing Company (Aug. 2000).Applicant
• Bass, S., and Yang, M., “Expressing cloned genes in Escherichia coli,” in Protein Function: A Practical Approach, 2nd ed., Creighton. T.E., ed., IRL Press, Oxford, Great Britain, pp. 29-55 (1997).Applicant
• Bernhagen, J., et al., “Purification, Bioactivity, and Secondary Structure Analysis of Mouse and Human Macrophage Migration Inhibitory Factor (MIF),” Biochemistry 33:14144-14155, American Chemical Society (1994).Applicant
• Biaselle, C.J., and Millar, D.B., “Studies on Triton X-100 detergent micelles,” Biophys. Chem. 3:355-361, North-Holland Publushing Company (1975).Applicant
• Bleul, C.C., et al., “The lymphocyte chemoattractant SDF-1 is a ligand for LESTR/fusin and blocks HIV-1 entry,” Nature 382:829-833, Nature Publishing Group (1996).Applicant
• Blomfield, I.C., et al., “Type 1 Fimbriation and fimE Mutants of Escherichia coli K-12,” J. Bacteriol. 173:5298-5307, American Society for Microbiology (1991).Applicant
• Blomfield, I.C., et al., “Integration host factor stimulates both FimB- and FimE- mediated site-specific DNA inversion that controls phase variation of type 1 fimbriae expression in Escherichia coli,” Mol. Microbiol. 23:705-717, Blackwell Science, Ltd. (1997).Applicant
• Boder, E.T., and Wittrup, K.D., “Yeast Surface Display for Directed Evolution of Protein Expression, Affinity, and Stability,” Methods Enzymol. 328:430-444, Academic Press (Oct. 2000).Applicant
• Bonci, A., et al., “Relatedness and Phylogeny Within the Family of Periplasmic Chaperones Involved in the Assembly of Pili or Capsule-Like Structures of Gram-Negative Bacteria,” J. Mol. Evol. 44:299-309, Springer-Verlag (1997).Applicant
• Brandner, S., et al., “A crucial role for B cells in neuroinvasive scrapie,” Transfus. Clin. Biol. 6:17-23, Elsevier, Paris (1999).Applicant
• Brinton, Jr., C.C., “The structure, function, synthesis and genetic control of bacterial pili and a molecular model for DNA and RNA transport in gram negative bacteria,” Trans. N.Y. Acad. Sci. 27:1003-1054, New York Academy of Sciences (1965).Applicant
• Brown, K.D., et al., “A family of small inducible proteins secreted by leukocytes are members of a new superfamily that includes leukocyte and fibroblast-derived inflammatory agents, growth factors, and indicators of various activation processes,” J. Immunol. 142:679-687, The American Association of Immulogists (1989).Applicant
• Brown, P.M., et al., “A Single-Step Purification of Biologically Active Recombinant Human Interleukin-5 from a Baculovirus Expression System,” Protein Expr. Purif. 6:63-71, Academic Press, Inc. (1995).Applicant
• Brown, K.L., et al., “Scrapie replication in lymphoid tissues depends on prion protein-expressing follicular dendritic cells,” Nat. Med. 11:1308-1312, Nature Publishing Company (1999).Applicant
• Bullitt, E., et al., “Development of pilus organelle subassemblies in vitro depends on chaperone uncapping of a beta zipper,” Proc. NatI. Acad. Sci. USA 93:12890-12895, National Academy Press (1996).Applicant
• Bullitt, E., and Makowski, L., “Bacterial Adhesion Pili Are Heterologous Assemblies of Similar Subunits,” Biophys. J. 74:623-632, Biophysical Society (1998).Applicant
• Burger, J.A., et al., “Blood-derived nurse-like cells protect chronic lymphocytic leukemia B cells from spontaneous apoptosis through stromal cell-derived factor-1,” Blood 96:2655-2663, The American Society of Hematology (Oct. 2000).Applicant
• Burghoff, R.L., et al., “Utilization of the Mouse Large Intestine To Select an Escherichia coli F-18 DNA Sequence That Enhances Colonizing Ability and Stimulates Synthesis of Type 1 Fimbriae,” Infect. Immun. 61:1293-1300, American Society for Microbiology (1993).Applicant
• Cannon-Carlson S., et al., “Expression, Purification, and Characterization of Recombinant Human Interleukin-13 from NS-O Cells,” Protein Expr. Purif. 12:239-248, Academic Press (1998).Applicant
• Chabaud, M., et al., “Enhancing Effect of IL-17 on IL-1-Induced IL-6 and Leukemia Inhibitory Factor Production by Rheumatoid Arthritis Synoviocytes and Its Regulation by Th2 Cytokines,” J. Immunol. 161: 409-414, The American Association of Immunologists (1998).Applicant
• Chabaud, M., et al., “Human Interleukin-17. A T Cell-Derived Proinflammatory Cytokine Produced by the Rheumatoid Synovium,” Arthritis Rheum. 42:963-970, Wiley-Liss, Inc. (1999).Applicant
• Chabaud, M., et al., “Contribution of Interleukin 17 to synovium matrix destruction in rheumatoid arthritis,” Cytokine 12:1092-1099, Cell Press (Jul. 2000).Applicant
• Clark, H.F, et al., “Comparative Characterization of a C-Type Virus-Producing Cell Line (VSW) and a Virus-Free Cell Line (VH2) From Vipera russelli,” J. Natl. Cancer Inst. 51:645-657, Oxford University Press (1973).Applicant
• Clark-Lewis, I., et al., “Chemical Synthesis, Purification, and Characterization of Two Inflammatory Proteins, Neutrophil Activating Peptide 1 (Interleukin-8) and Neutrophil Activating Peptide 2,” Biochemistry 30:3128-3135, American Chemical Society (1991).Applicant
• Coffman, R.L., et al., “Antibody to Interleukin-5 Inhibits Helminth-Induced Eosinophilia in Mice,” Science 245:308-310, American Association for the Advancement of Science (1989).Applicant
• Cohen, C., and Parry D.A.D, “α-Helical coiled coils-a widespread motif in proteins,” Trends Biochem. Sci. 11:245-248, Elsevier Science Publishers B.V. (1986).Applicant
• Corti, M., et al., “GM1-ganglioside-Triton X-100 mixed micelles: changes of micellar properties studied by laser-light scattering and enzymatic methods,” Chem. Phys. Lipids 28:197-214, Elsevier/North-Holland Scientific Publishers, Ltd. (1981).Applicant
• Coutelier, J.-P., et al., “IgG2a Restriction of murine antibodies elicited by viral infections,” J. Exp. Med. 165:64-69, The Rockefeller University Press (1987).Applicant
• Crump, M.P., et al., “Solution Structure of Eotaxin, a Chemokine That Selectively Recruits Eosinophils in Allergic Inflammation,” J. BioI. Chem. 273:22471-22479, The American Society for Biochemistry and Molecular Biology, Inc. (1998).Applicant
• Davis, N.L., et al., “In Vitro Synthesis of Infectious Venezuelan Equine Encephalitis Virus RNA from a cDNA Clone: Analysis of a Viable Deletion Mutant,” Virology 171:189-204, Academic Press (1989).Applicant
• Daugherty, P.S., et al., “Development of an optimized expression system for the screening of antibody libraries displayed on the Escherichia coli surface,” Protein Eng. 12:613-621, Oxford University Press (1999).Applicant
• Dealwis, C., et al., “Crystal structure of chemically synthesized [N33A] stromal cell-derived factor 1α, a potent ligand for the HIV-1 “fusin” coreceptor,” Proc. Natl. Acad. Sci. USA 95:6941-6946, National Academy Science (Jun. 2001).Applicant
• Dodson, K.W., et al., “Outer-membrane PapC molecular usher discriminately recognizes periplasmic chaperone-pilus subunit complexes,” Proc. Natl. Acad. Sci. USA 90:3670-3674, National Academy Press (1993).Applicant
• Dudler, J., et al., “Effect of interleukin 17 on proteoglycan degradation in murine knee joints,” Ann. Rheum. Dis. 59:529-532, Bmj Publishing Group (Jul. 2000).Applicant
• Eckhardt, S.G., et al., “Hepatitis B Virus Core Antigen Has Two Nuclear Localization Sequences in the Arginine-Rich Carboxyl Terminus,” J. Virol. 65:575-562, American Society for Microbiology (1991).Applicant
• Eisenmesser, E.Z., et al., “Expression, Purification, Refolding, and Characterization of Recombinant Human Interleukin-13: Utilization of Intracellular Processing,” Protein Expr. Purif. 20:186-195, Academic Press (Nov. 2000).Applicant
• Eisenmesser, E.Z., et al., “Solution Structure of Interleukin-13 and Insights into Receptor Engagement,” J. Mol. Biol. 310:231-241, Academic Press (Jun. 2001).Applicant
• Eisenstein, B.I., “Phase Variation of Type 1 Fimbriae in Escherichia coli Is Under Transcriptional Control,” Science 214:337-339, American Association for the Advancement of Science (1981).Applicant
• Elisseeva, E.L., et al., “NMR Studies of Active N-terminal Peptides of Stromal Cell-derived Factor-1,” J. Biol. Chem. 275:26799-26805, The American Society for Biochemistry and Molecular Biology, Inc. (Sep. 2000).Applicant
• Eshdat, Y., et al., “Dissociation and Reassembly of Escherichia coli Type 1 Pili,” J. Bacteriol. 148:308-314, American Society for Microbiology (1981).Applicant
• Ettinger, R., et al., “A Critical Role for Lymphotoxin-β Receptor in the Development of Diabetes in Nonobese Diabetic Mice,” J. Exp. Med. 193:1333-1339, The Rockefeller University Press (Jun. 2001).Applicant
• Fehr, T., et al., “Role of Repetitive Antigen Patterns for Induction of Antibodies Against Antibodies,” J Exp. Med. 185:1785-1792, The Rockefeller University Press (1997).Applicant
• Folkman, J., and Klagsbrun, M., “Angiogenic Factors,” Science 235:442-447, American Association for the Advancement of Science (1987).Applicant
• Folkman, J., “Angiogenesis in cancer, vascular, rheumatoid and other disease,” Nat. Med. 1:27-31, Nature Publishing Company (1995).Applicant
• Forssmann, U., et al., “Eotaxin-2, a Novel CC Chemokine that Is Selective for the Chemokine Receptor CCR3, and Acts Like Eotaxin on Human Eosinophil and Basophil Leukocytes,” J. Exp. Med. 185:2171-2176, The Rockefeller University Press (1997).Applicant
• Fossiez, F., et al., “T Cell Interleukin-17 Induces Stromal Cells to Produce Proinflammatory and Hematopoietic Cytokines,” J. Exp. Med. 183:2593-2603, The Rockefeller University Press (1996).Applicant
• Fossiez F., et al., “Interleukin-17,” Intern. Rev. Immunol. 16:541-551, Harwood Academic Publishers (1998).Applicant
• Fujiwara, K., et al., “Novel preparation method of immunogen for hydrophobic hapten, enzyme immunoassay for daunomycin and adriamycin,” J. Immunol. Methods 45:195-203, Elsevier/North-Holland Biomedical Press (1981).Applicant
• Gally, D.L., et al., “Environmental Regulation of the fim Switch Controlling Type 1 Fimbrial Phase Variation in Escherichia coli K-12: Effects of Temperature and Media,” J. Bacteriol. 175:6186-6193, American Society for Microbiology (1993).Applicant
• Gally, D. L., et al., “Interaction of FimB and FimE with the fim switch that controls the phase variation of type 1 fimbriate in Escherichia coli K-12,” MoI. Microbiol. 21:725-738, Blackwell Science, Ltd. (1996).Applicant
• Gherardi, E. et al., “A single-step procedure for cloning and selection of antibody-secreting hybridomas,” J. lmmunol. Methods 126: 61-68, Elsevier (1990).Applicant
• Golmohammadi, R., et al., “The crystal structure of bacteriophage Qβ at 3.5Å resolution,” Structure 4:543-554, Current Biology, Ltd. (1996).Applicant
• Gunn, M.D., et al., “A B-cell-homing chemokine made in lymphoid follicles activates Burkitt's lymphoma receptor-1,” Nature 391:799-803, Nature Publishing Group (1998).Applicant
• Hanes, J., et al., “Picomolar affinity antibodies from a fully synthetic naive library selected and evolved by ribosome display,” Nat. Biotechnol. 18:1287-1292, Nature Publishing Company (Dec. 2000).Applicant
• Hanson, M.S., et al., “Purification of the Escherichia coli Type 1 Pilin and Minor Pilus Proteins and Partial Characterization of the Adhesin Protein,” J. Bacteriol. 170:3350-3358, American Society for Microbiology (1988).Applicant
• Hanson, M.S., and Brinton, Jr., C.C., “Identification and characterization of E. coli type-1 pilus tip adhesion protein,” Nature 332:265-268, Nature Publishing Group (1988).Applicant
• Harrison, J.L., et aI., “Screening of Phage Antibody Libraries,” Methods Enzymol. 267:83-109, Macmillan Publishers, Ltd. (1996).Applicant
• Haslam, D.B., et al., “The amino-terminal domain of the P-pilus adhesin determines receptor specificity,” Mol. Microbiol. 14:399-409, Blackwell Scientific Publications (1994).Applicant
• Hedrick, J.A., and Zlotnik, A., “Identification and Characterization of a Novel β Chemokine Containing Six Conserved Cysteines,” J. Immunol. 159: 1589-1593, The American Association of Immunologists (1997).Applicant
• Heveker, N., et al., Dissociation of the signalling and antiviral properties of SDF-1-derived small peptides, Curr. Biol. 8:369-376, Current Biology, Ltd. (1998).Applicant
• Hirel, P.-H., et al., “Extent of N-terminal methionine excision from Escherichia coli proteins is governed by the side-chain length of the penultimate amino acid,” Proc. Natl. Acad. Sci. USA 86:8247-8251, National Academy Press (1989).Applicant
• Holmes, W.D., et al., “Solution Studies of Recombinant Human Stromal-Cell-Derived Factor-1,” Prot. Expr. Purif. 21:367-377, Academic Press (Apr. 2001).Applicant
• Holmgren, A., et al., “Conserved immunoglobulin-like features in a family of periplasmic pilus chaperones in bacteria,” EMBO J. 11:1617-1622, Oxford University Press (1992).Applicant
• Holmgren, A., and Bränden, C.-I., “Crystal structure of chaperone protein PapD reveals an immunoglobulin fold,” Nature 342:248-251, Nature Publishing Group (1989).Applicant
• Hultgren, S.J., et al., “The PapG adhesin of uropathogenic Escherichia coli contains separate regions for receptor binding and for the incorporation into the pilus,” Proc. Nat. Acad. Sci. USA 86:4357-4361, National Academy Press (1989).Applicant
• Hultgren, S.J., et al., “PapD and superfamily of periplasmic immunoglobulin-like pilus chaperones,” Adv. Prot. Chem. 44:99-123, Academic Press, Inc. (1993).Applicant
• Hultgren, S.J., et al., “Pilus and Nonpilus Bacterial Adhesins: Assembly and Function in Cell Recognition,” Cell 73:887-901, Cell Press (1993).Applicant
• Hultgren, S.J., et al., “Bacterial Adhesins and Their Assembly,” in Escherichia coli and Salmonella, Neidhardt, P.C., et al., eds., ASM Press, Washington, D.C. pp. 2730-2756 (1996).Applicant
• Humbles, A.A., et al., “Kinetics of Eotaxin Generation and Its Relationship to Eosinophil Accumulation in Allergic Airways Disease: Analysis in a Guinea Pig Model In Vivo,” J. Exp. Med. 186:601-612, The Rockefeller University Press (1997).Applicant
• Hung, D.L., et al., “Molecular basis of two subfamilies of immunoglobulin-like chaperones,” EMBO J. 15:3792-3805, Oxford University Press (1996).Applicant
• Hung, D.L. and Hultgren, S.J., “Pilus Biogenesis via the Chaperone/Usher Pathway: An Integration of Structure and Function,” J. Struct. Biol. 124:201-220, Academic Press (1998).Applicant
• Ikeda, T., et al., “Determination of Three Isoforms of the Receptor Activator of Nuclear Factor-κB Ligand and Their Differential Expression in Bone and Thymus,” Endocrinology 142:1419-1426, The Endocrine Society (Apr. 2001).Applicant
• Ingley E., et al., “Production and purification of recombinant human interleukin-5 from yeast and baculovirus expression systems,” Eur. J. Biochem. 196:623-629, Blackwell Science, Ltd. (1991).Applicant
• Jacob-Dubuisson, F., et al., “PapD chaperone function in pilus biogenesis depends on oxidant and chaperone-like activities of DsbA,” Proc. Natl. Acad. Sci. USA 91:11552-11556, National Academy Press (1994).Applicant
• Jacob-Dubuisson, F., et al., “Initiation of assembly and association of the structural elements of a bacterial pilus depend on two specialized tip proteins,” EMBO J. 12:837-847, Oxford University Press (1993).Applicant
• Jacob-Dubuisson, F., et al., “Chaperone-assisted Self-assembly of Pili Independent of Cellular Energy,” J. Biol. Chem. 269:12447-12455, The American Society for Biochemistry and Molecular Biology, Inc. (1994).Applicant
• Jiang, X., et al., “Norwalk Virus Genome Cloning and Characterization,” Science 250:1580-1583, American Association for the Advancement of Science (1990).Applicant
• Jones, C.H., et al., “FimC is a periplasmic PapD-like chaperone that directs assembly of type 1 pili in bacteria,” Proc. Natl. Acad. Sci. USA 90:8397-8401, National Academy Press (1993).Applicant
• Jones, C.H., et al., “FimH adhesin of type 1 pili is assembled into a fibrillar tip structure in the Enterobacteriaceae,” Proc. Natl. Acad. Sci. USA 92:2081-2085, National Academy Press (1995).Applicant
• Josien, R., et al., “TRANCE, a Tumor Necrosis Factor Family Member, Enhances the Longevity and Adjuvant Properties of Dendritic Cells In Vivo,” J. Exp. Med. 191: 495-501, The Rockefeller University Press (Feb. 2000).Applicant
• Jovanovic, D.V., et al., “IL-17 Stimulates the Production and Expression of Proinflammatory Cytokines, IL-β and TNF-α, by Human Macrophages,” J. Immunol. 160:3513-3521, The American Association of Irnmunologists (1998).Applicant
• Kapp, U., et al., “Interleukin 13 Is Secreted by and Stimulates the Growth of Hodgkin and Reed-Sternberg Cells,” J. Exp. Med. 189:1939-1945, The Rockefeller University Press (1999).Applicant
• Kastelein, R.A. et al., “Effect of the sequence upstream from the ribosome-binding site on the yield of protein from the cloned gene for phage MS2 coat protein,” Gene 23:245-254, Elsevier (1983).Applicant
• Kim, K.J., et al., “Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo,” Nature 362:841-844, Nature Publishing Group (1993).Applicant
• Kim, K.-H., et al., “A Cysteine-rich Adipose Tissue-specific Secretory Factor Inhibits Adipocyte Differentiation,” J. Biol. Chem. 276:11252-11256, The American Society for Biochemistry and Molecular Biology, Inc. (Apr. 2001).Applicant
• Klemm, P., “The fimA gene encoding the type-1 fimbrial subunit of Escherichia coli. Nucleotide sequence and primary structure of the protein,” Euro. J. Biochem. 143:395-399, Blackwell Science, Ltd. (1984).Applicant
• Klemm, P., and Christiansen, G., “Three fim genes required for the regulation of length and mediation of adhesion of Escherichia coli type 1 fimbriae,” Mol. Gen. Genet. 208:439-445, Springer-Verlag (1987).Applicant
• Klemm, P., et al., “The major subunit of Escherichia coli type 1 fimbriate is not required for D-mannose-specific adhesion,” Mol. Microbiol. 4:553-559, Blackwell Scientific Publications (1990).Applicant
• Klemm, P., and Christiansen, G., “The fimD gene required for cell surface localization of Escherichia coli type 1 fimbriae,” Mol. Gen. Genet. 220:334-338, Springer-Verlag (1990).Applicant
• Klemm, P., “FimC, a chaperone-like periplasmic protein of Escherichia coli involved in biogenesis of type 1 fimbriae,” Res. Microbiol. 143:831-838, Institut Pasteur/Elsevier (1992).Applicant
• Klemm, P., and Krogfelt, K.A., “Type 1 Fimbriae of Escherichia coli,” in Fimbriae, Klemm, P., ed., CRC Press, Inc., Boca Raton, FL., pp. 9-26 (1994).Applicant
• Kodama, S., et al., “Characterization of recombinant murine interleukin 5 expressed in Chinese hamster ovary cells,” GIycobiology 2:419-427, Oxford University Press (1992).Applicant
• Kodama, S., et al., “Carbohydrate Structures of Human Interleukin 5 Expressed in Chinese Hamster Ovary Cells,” J. Biochem. (Tokyo) 110:693-701, Japanese Biochemical Society (1991).Applicant
• Kopf, M., et al., “IL-5-Deficient Mice Have a Developmental Defect in CD5′ B-1 Cells and Lack Eosinophilia but have Normal Antibody and Cytotoxic T Cell Responses,” Immunity 4:15-24, Cell Press (1996).Applicant
• Koschel, M., et al., “Extensive Mutagenesis of the Hepatitis B Virus Core Gene and Mapping of Mutations That Allow Capsid Formation,” J. Virol 73:2153-2160, American Society for Microbiology (1999).Applicant
• Koths, K., “Structure-Function Studies on Human Macrophage Colony-Stimulating Factor (M-CSF),” Mol. Reprod. Dev. 46:31-38, Wiley-Liss, Inc. (1997).Applicant
• Kozlovska, T.M., et al., “Recombinant RNA phage Qβ capsid particles synthesized and self-assembled in Escherichia coli,” Gene 137:133-137, Elsevier Science Publishers B.V. (1993).Applicant
• Kozlovskaya, T.M., et al., “Formation of capsid-like structures as a result of the expression of a cloned envelope protein gene from RNA-containing bacteriophage fr,” DokI. Akad. Nauk. SSSR 287: 452-455, Erivan Akademiia Nauk Armianskoi Ssr (1986).Applicant
• Kozlovskaya, T.M., et al., “Formation of capsid-like structures as a result of the expression of a cloned envelope protein gene from RNA-containing bacteriophage fr,” STNEasy, Accession No. 1986:219892, CAplus English abstract (1986) (Document AT37).Applicant
• Krogfelt, KA., et al., “Direct Evidence that the FimH Protein Is the Mannose-Specific Adhesin of Escherichia coli Type 1 Fimbriae,” Infect. lmmun. 58:1995-1998, American Society for Microbiology (1990).Applicant
• Kuehn, M.J., et al., “Structural Basis of Pilus Subunit Recognition by the PapD Chaperone,” Science 262:1234-1241, American Association for the Advancement of Science (1993).Applicant
• Lee, K.H., et al., “Two-Dimensional Electrophoresis of Proteins as a Tool in the Metabolic Engineering of Cell Cycle Regulation,” Biotech. Bioeng. 50:336-340, John Wiley & Sons, Inc. (1996).Applicant
• Leech, M., et al., “Involvement of macrophage migration inhibitory factor in the evolution of rat adjuvant arthritis,” Arthritis Rheum. 41:910-917, Arthritis Foundation (1998).Applicant
• Leech, M., et al. “Regulation of macrophage migration inhibitory factor by endogenous glucocorticoid in rat adjuvant-induced arthritis,” Arthritis Rheum. 43:827-833, Arthritis Foundation (Apr. 2000).Applicant
• Kunimoto, D.Y, et al., “High-level production of murine interleukin-5 (IL-5) utilizing recombinant baculovirus expression. Purification of the rIL-5 and its use in assessing the biologic role of IL-5 glycosylation,” Cytokine 3:224-230, W.B. Saunders Company (1991).Applicant
• Landschulz, W.H., et al., “The Leucine Zipper: A Hypothetical Structure Common to a New Class of DNA Binding Proteins,” Science 240:1759-1764, American Association for the Advancement of Science (1988).Applicant
• Leake, C.J., et al., “Cytopathic Effect and Plaque Formation by Arboviruses in a Continuous Cell Line (XTC-2) from the Toad Xenopus Iaevis,” J. gen. Virol. 35:335-339, Cambridge University Press (1977).Applicant
• Liljeström, P., and Garoff, H., “A new generation of animal cell expression vectors based on the semliki forest virus replicon,” Bio/technology 9:1356-1361, Nature Publishing Company (1991).Applicant
• Liljeström, P., “Alphavirus expression systems,” Curr. Opin. BiotechnoI. 5:495-500, Current Biology, Ltd. (1994).Applicant
• Lim, F., et al., “The RNA-binding Site of Bacteriophage Qβ Coat Protein,” J. Biol. Chem. 271:31839-31845, The American Society for Biochemistry and Molecular Biology, Inc. (1996).Applicant
• López, O., et al., “Direct formation of mixed micelles in the solubilization of phospholipid liposomes by Triton X-100,” FEBS Lett. 426:314-318, Elsevier (1998).Applicant
• Lowe, M.A., et al., “lmmunoelectron Microscopic Analysis of Elongation of Type 1 Fimbriae in Escherichia coli,” J. Bacteriol. 169:157-163, American Society for Microbiology (1987).Applicant
• Lu, D., et al., “Identification of the Residues in the Extracellular Region of KDR Important for Interaction with Vascular Endothelial Growth Factor and Neutralizing Anti-KDR Antibodies,” J. Biol. Chem. 275:14321-14330, The American Society for Biochemistry and Molecular Biology, Inc. (May 2000).Applicant
• Lin, E.Y., et al., “Colony-stimulating Factor 1 Promotes Progression of Mammary Tumors to Malignancy,” J. Exp. Med. 193:727-739, The Rockefeller University Press (Mar. 2001).Applicant
• Lindberg, F., et al., “PapD, a Periplasmic Transport Protein in P-Pilus Biogenesis,” J. Bacteriol. 171:6052-6058, American Society for Microbiology (1989).Applicant
• Lo-Man, R., et al., “A recombinant virus-like particle system derived from parvovirus as an efficient antigen carrier to elicit a polarized Thl immune response without adjuvant,” Eur. J. Immunol. 28:1401-1407, Wiley-VCH Verlag GmbM (1998).Applicant
• Lum, L., et al., “Evidence for a Role of a Tumor Necrosis Factor-α (TNF-α)-converting Enzyme-like Protease in Shedding of TRANCE, a TNF Family Member Involved in Osteoclastogenesis and Dendritic Cell Survival,” J. Biol. Chem. 274:13613-13618, The American Society for Biochemistry and Molecular Biology, Inc. (1999).Applicant
• Lundstrom, K., “Alphaviruses as expression vectors,” Curr. Opin. Biotechnol. 8:578-582, Current Biology, Ltd. (1997).Applicant
• Luther, S.A., et al., “BLC Expression in Pancreatic Islets Causes B Cell Recruitment and Lymphocoxin-Dependent Lymphoid Neogenesis,” Immunity 12:471-481, Cell Press (May 2000).Applicant
• Mackay, J.L., and Browning, J.L., “Turning off follicular dendritic cells,” Nature 395:26-27, Macmillan Magazines, Ltd. (1998).Applicant
• Martiny-Baron, G., and Marmé, D., “VEGF-mediated tumour angiogenesis: a new target for cancer therapy,” Curr. Opin. Biotechnol. 6:675-680, Current Biology, Ltd. (1995).Applicant
• Matsui, S.M., et al., “The Isolation and Characterization of a Norwalk Virus-Specific cDNA,” J. Clin. Invest. 87:1456-1461, The American Society for Clinical Investigation, Inc. (1991).Applicant
• Matsumoto, M., et al., “Role of Lymphotoxin and the Type 1 TNF Receptor in the Formation of Germinal Centers,” Science 271:1289-1291, American Association for the Advancement of Science (1996).Applicant
• Matthews, W., et al., “A receptor tyrosine kinase cDNA isolated from a population of enriched primitive hematopoietic cells and exhibiting close genetic linkage to c-kit,” Proc. Natl. Acad. Sci. USA 88:9026-9030, National Academy Press (1991).Applicant
• Matusevicius, D., et al., “Interleukin-17 mRNA expression in blood and CSF mononuclear cells is augmented in multiple sclerosis, ” Mult. Scler. 5:101-104, Stockton Press (1999).Applicant
• Mayer, K.L., and Stone, M.J., “NMR Solution Structure and Receptor Peptide Binding of the CC Chemokine Eotaxin-2,” Biochemistry 39:8382-8395, American Chemical Society (Jul. 2000).Applicant
• McClain, M.S., et al., “Roles of fimB and fimE in Site-Specific DNA Inversion Associated with Phase Variation of Type 1 Fimbriae in Escherichia coli,” J. Bacteriol. 173:5308-5314, American Society for Microbiology (1991).Applicant
• McPherson, P.S., “Regulatory Role of SH3 Domain-mediated Protein-Protein Interactions in Synaptic Vesicle Endocytosis,” Cell Signal 11:229-238, Elsevier Science, Inc. (1999).Applicant
• Mikulowaka, A., et al., “Macrophage Migration Inhibitory Factor Is Involved in the Pathogenesis of Collagen Type Il-Induced Arthritis in Mice,” J. Immunol. 158:5514-5517, The American Association of Immunologists (1997).Applicant
• Millauer, B., et al., “Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant,” Mature 367:576-579, Nature Publishing Group (1994).Applicant
• Min, H., et al., “Osteoprotegerin Reverses Osteoporosis by Inhibiting Endosteal Osteoclasts and Prevents Vascular Calcification by Blocking a Process Resembling Osteoclastogenesis,” J. Exp. Med. 192:463-474, The Rockefeller University Press (Aug. 2000).Applicant
• Mitchell, D.L., et al., “Purification and characterization of recombinant murine interleukin-5 glycoprotein, from a Baculovirus expression system,” Biochem. Soc. Trans. 21:332S, Portland Press (1993).Applicant
• Montrasio, F. et al., “Impaired Prion Replication in Spleens of Mice Lacking Functional Follicular Dendritic Cells,” Science 288:1257-1259, American Association for the Advancement of Science (May 2000).Applicant
• Morein, B., et al., “Iscom, a novel structure for antigenic presentation of membrane proteins from enveloped viruses,” Nature 308:457-460, Nature Publishing Group (1984).Applicant
• Moriya, C., et al., “Large quantity production with extreme convenience of human SDF-1α and SDF-1β by a Sendai virus vector,” FEBS Lett. 425:105-111, Amsterdam Elsevier Science B.V. (1998).Applicant
• Müller, A., et al., “Involvement of chemokine receptors in breast cancer metastasis,” Nature 410:50-56, Nature Publishing Group (Mar. 2001).Applicant
• Murphy, Jr., K.P., et al., “Expression of Human Interleukin-17 in Pichia pastoris: Purification and Characterization,” Protein Expr. Purif. 12:208-214, Academic Press (1998).Applicant
• Nagira, M., et al., “Molecular Cloning of a Novel Human CC Chemokine Secondary Lymphoid-Tissue Chemokine That Is a Potent Chemoattractant for Lymphocytes and Mapped to Chromosome 9p13,” J. Biol. Chem. 272:19518-19524, The American Society for Biochemistry and Molecular Biology, Inc. (1997).Applicant
• Nanki, T., et al., “Stromal Cell-Derived Factor-1-CXC Chemokine Receptor 4 Interactions Play a Central Role in CD4+ T Cell Accumulation in Rheumatoid Arthritis Synovium,” J. Immunol. 165:6590-6598, The American Association of Immunologists (Dec. 2000).Applicant
• Naureckiene, S., and Uhlin., B.E., “In vitro analysis of mRNA processing by Rnase E in the pap operon of Esherichia coli,” Mol. Microbiol. 21:55-68, Blackwell Science, Ltd. (1996).Applicant
• Neirynck, S., et al., “A universal influenza A vaccine based on the extracellular domain of the M2 protein,” Nat. Med. 5:1157-1163, Nature Publishing Company (1999).Applicant
• Newman, J.V., et al., “Stimulation of Escherichia coli F-18Col Type-1 fimbriae synthesis by IeuX,” FEMS Microbiol. Lett. 122:281-287, Elsevier (1994).Applicant
• Ni, C. -Z., et al., “Crystal structure of the coat protein from the GA bacteriophage: Model of the unassembled dimer,” Protein Sci. 5:2485-2493, Cambridge University Press (1996).Applicant
• Nilsson, P., et al., “Mutations Affecting mRNA Processing and Fimbrial Biogenesis in the Escherichia coli pap Operon,” J. Bacteriol. 178:683-690, American Society for Microbiology (1996).Applicant
• Oberlin, S., et al., “The CXC chemokine SDF-1 is the ligand for LESTR/fusin and prevents infection by T-cell-line-adapted HIV-1,” Nature 382:833-835, Nature Publishing Group (1996).Applicant
• Ohnishi, Y., at al., “Crystal Structure of Recombinant Native SDF-1α with Additional Mutagenesis Studies: An Attempt at a More Comprehensive Interpretation of Accumulated Structure-Activity Relationship Data,” J. Interferon Cytokine Res. 20:691-700, Mary Ann Liebert, Inc. (Aug. 2000).Applicant
• Olszewska, W., et al., “Protection against Measles Virus-Induced Encephalitis by Anti-mimotope Antibodies: The Role of Antibody Affinity,” Virology 272:98-105, Academic Press (Jun. 2000).Applicant
• Orndorff, P.E., and Falkow, S., “Identification and Characterization of a Gene Product That Regulates Type 1 Piliation in Escherichia coli,” J. Bacteriol. 160:61-66, American Society for Microbiology (1984).Applicant
• Orndorff, P.E., and Falkow, S., “Nucleotide Sequence of pilA, the Gene Encoding the Structural Component of Type 1 Pili in Escherichia coli,” J. Bacteriol. 162:454-457, American Society for Microbiology (1985).Applicant
• O'Shea, E.K., et al., “Evidence That the Leucine Zipper Is a Coiled Coil,” Science 243:538-542, American Association for the Advancement of Science (1989).Applicant
• O'Shea, E.K., et al., “Mechanism of Specificity in the Fos-Jun Oncoprotein Heterodimer,” Cell 68:699-708, Cell Press (1992).Applicant
• Pandit, J., et al., “Three-dimensional Structure of Dimeric Human Recombinant Macrophage Colony-Stimulating Factor,” Science 258:1358-1362, American Association for the Advancement of Science (1992).Applicant
• Pierrot, C., et al., “Expression of Rat Interleukin-5 and Generation of Neutralizing Antiserum: a Comparative Study of Rat IL-5 Produced in Escherichia coli and Insect Cells,” Biochem. Biophys. Res. Commun. 253:756-760, Academic Press (1998).Applicant
• Pierson-Mullany, L.K., et al. “Characterization of polyclonal allergen-specific IgE responses by affinity distributions,” Mol. Immunol. 37:613-620, Elsevier Science, Ltd. (Aug. 2000).Applicant
• Piossek, C., et al., “Vascular Endothelial Growth Factor (VEGF) Receptor II-derived Peptides Inhibit VEGF,” J. Biol. Chem. 274:5612-5619, The American Society for Biochemistry and Molecular Biology, Inc. (1999).Applicant
• Presta, L.G., et al., “Humanization of an Anti-Vascular Endothelial Growth Factor Monoclonal Antibody for the Therapy of Solid Tumors and Other Disorders,” Cancer Res. 57:4593-4599, The American Association for Cancer Research (1997).Applicant
• Priano, C., et al., “A Complete Plasmid-based Complementaion System for RNA Coliphage Qβ: Three Proteins of Bacteriophages Qβ (Group III) and SP (Group IV) can be Interchanged,” J. Mol. Biol. 249:283-297, Academic Press, Ltd. (1995).Applicant
• Proudfoot, A.E.I., et al., “Preparation and characterization of human interleukin-5 expressed in recombinant Escherichia coli,” Biochem. J. 270:357-361, Portland Press, Ltd. (1990).Applicant
• Renner, W.A., et al., “Recombinant Cyclin E Expression Activates Proliferation and Obviates Surface Attachment of Chinese Hamster Ovary (CHO) Cells in Protein-Free Medium,” Biotech. Bioeng. 47:476-482, John Wiley & Sons, Inc. (1995).Applicant
• Risau, W., “Mechanisms of angiogenesis,” Nature 386:671-674, Nature Publishing Group (1997).Applicant
• Ritter, A., et al., “The Pai-associated leuX specific tRNA5Leu affects type 1 fimbriation in pathogenic Escherichia coli by control of FimB recombinase expression,” Mol. Microbiol. 25:871-882, Blackwell Science, Ltd. (1997).Applicant
• Roesch, P.L., and Blomfield, I.C., “Leucine alters the interaction of the leucine-responsive regulatory protein (Lrp) with the fim switch to stimulate site-specific recombination in Escherichia coli,” Mol. Microbiol. 27:751-761, Blackwell Science, Ltd. (1998).Applicant
• Roher, A.E., et al., “Isolation and Chemical Characterization of Alzheimer's Disease Paired Helical Filament Cytoskeletons: Differentiation from Amyloid Plaque Core Protein,” J. Cell Biol. 107:2703-2716, The Rockefeller University Press (1988).Applicant
• Roher, A.E., et al., “Morphological and Biochemical Analyses of Amyloid Plaque Core Proteins Purified from Alzheimer Disease Brain Tissue,” J. Neurochem. 61: 1916-1926, Raven Press, Ltd. (1993).Applicant
• Romagnani, S., “The Th1/Th2 paradigm,” Immunol. Today 18:263-266, Elsevier Science, Ltd. (1997).Applicant
• Rothenberg, M.E., et al., “Targeted Disruption of the Chemokine Eotaxin Partially Reduces Antigen-induced Tissue Eosinophilia,” J. Exp. Med. 185:785-790, The Rockefeller University Press (1997).Applicant
• Rusconi, S., et al., “In vitro inhibition of HIV-1 by Met-SDF-1β alone or in combination with antiretroviral drugs,” Antivir. Ther. 5:199-204, International Medical Press (Sep. 2000).Applicant
• Russell, P.W., and Orndorff, P.E., “Lesions in Two Escherichia coli Type 1 Pilus Genes Alter Pilus Number and Length without Affecting Receptor Binding,” J. Bacteriol. 174:5923-5935, American Society for Microbiology (1992).Applicant
• Santos, L., et al., “Role of macrophage migration inhibitory factor (MIF) in murine antigen-induced arthritis: interaction with glucocorticoids,” Clin. Exp. Immunol. 123:309-314, Blackwell Science (Feb. 2001).Applicant
• Saulino, E.T., et al., “Ramifications of kinetic partitioning on usher-mediated pilus biogenesis,” EMBO J. 17:2177-2185, Oxford University Press (1998).Applicant
• Schenk, D., et al., “Immunization with amyloid-β attenuates Alzheimer-diseaee-like pathology in the PDAPP mouse,” Nature 400:173-177, Nature Publishing Group (1999).Applicant
• Schlesinger, S., “Alphaviruses—vectors for the expression of heterologous genes,” Trends Biotechnol. 11:18-22, Elsevier Science Publishers, Ltd. (1993).Applicant
• Selkoe, D.J., “Translating cell biology into therapeutic advances in Alzheimer's disease,” Nature 399:A23-A31, Nature Publishing Group (1999).Applicant
• Slonim, L.N., et al., “Interactive surface in the PapD chaperone cleft is conserved in pilus chaperone superfamily and essential in subunit recognition and assembly,” EMBO J. 11:4747-4756, Oxford University Press (1992).Applicant
• Smyth, C.J., et al., “Fimbrial adhesins: similarities and variations in structure and biogenesis,” FEMS Immun. Med. Microbiol. 16:127-139, Elsevier (1996).Applicant
• Soto, H., et al., “The CC chemokine 6Ckine binds the CXC chemokine receptor CXCR3,” Proc. Natl. Acad. Sci. USA 95:8205-8210, National Academy Press (1998).Applicant
• Soto, G.E., et al., “Periplasmic chaperone recognition motif of subunits mediates quaternary interactions in the pilus,” EMBO J. 17:6155-6167, Oxford University Press (1998).Applicant
• Soto, G.E., and Hultgren, S.J., “Bacterial Adhesins: Common Themes and Variations in Architecture and Assembly,” J. Bacteriol. 181:1059-1071, American Society for Microbiology (1999).Applicant
• Steppan, C.M., et al., “The hormone resistin links obesity to diabetes,” Nature 409:307-312, Nature Publishing Group (Jan. 2001).Applicant
• Stollar, V., “Togaviruses in Cultured Arthropod Cells,” in The Togaviruses, Biology, Structure, Replication, Schlesinger, R.W., ed., Academic Press, Inc. New York, N.Y., pp. 583-621 (1980).Applicant
• Strauss, J., and Strauss, E.G., “The Alphaviruses: Gene Expression, Replication, and Evolution,” Microbiol. Rev. 58:491-562, American Society for Microbiology (1994).Applicant
• Striker, R.T., et al., “Stable Fiber-forming and Nonfiber-forming Chaperone-Subunit Complexes in Pilus Biogenesis,” J. Biol. Chem. 269:12233-12239, The American Society for Biochemistry and Molecular Biology, Inc. (1994).Applicant
• Sturchler-Pierrat, C., et al., “Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology,” Proc. Natl. Acad. Sci. USA 94:13287-13292, National Academy Press (1997).Applicant
• Sun, H.-W., et al., “Crystal structure at the 2.6-Å resolution of human macrophage migration inhibitory factor,” Proc. Natl. Acad. Sci. USA 93:5191-5196, National Academy Press (1996).Applicant
• Tang, J. -L., et al., “Interleukin-17 antagonism inhibits acute but not chronic vascular rejection,” Transplantation 72:348-350, Lippincott Williams & Wilkens (Jul. 2001).Applicant
• Tanimori, H., et al., “Enzyme immunoassay of neocarzinostatin using β-galactosidase as label,” J. Pharm. Dyn. 4:812-819, Pharmaceutical Society of Japan (1981).Applicant
• Teixeira, M.M., et al., “Chemokine-induced Eosinophil Recruitment. Evidence of a Role for Endogenous Eotaxin in an In Vivo Allergy Model in Mouse Skin,” J. Clin. Invest. 100:1657-1666, The American Society for Clinical Investigation, Inc. (1997).Applicant
• Tewari, R., et al., “Neutrophil Activation by Nascent FimH Subunits of Type I Fimbriae Purified from the Periplasm of Escherichia coli,” J. Biol. Chem. 268:3009-3015, The American Society for Biochemistry and Molecular Biology, Inc. (1993).Applicant
• Teunissen, M.B.M., et al., “Interleukin-17 and Interferon-Γ Synergize in the Enhancement of Proinflammatory Cytokine Production by Human Keratinocytes,” J. Invest. Dermatol. 111:645-649, The Society for Investigative Dermatology, Inc. (1998).Applicant
• Thanassi, D.C., et al., “The PapC usher forms an oligomeric channel: Implications for pilus biogenesis across the outer membrane,” Proc. Natl. Acad. Sci. USA 95:3146-3151, National Academy Press (1998).Applicant
• De Togni, P., et al., “Abnormal Development of Peripheral Lymphoid Organs in Mice Deficient in Lymphotoxin,” Science 264:703-707, American Association for the Advancement of Science (1994).Applicant
• Topchieva, I., and Karezin, K., “Self-Assembled Supramolecular Micellar Structures Based on Non-ionic Surfactants and Cyclodextrins,” J. CoIloid Interface Sci. 213:29-35, Academic Press (1999).Applicant
• Twomey, T., et al., “Structure and immunogenicity of experimental foot-and-mouth disease and poliomyelitis vaccines,” Vaccine 13:1603-1610, Elsevier Science, Ltd. (1995).Applicant
• Ulrich, R., et al., “Core particles of hepatitis B virus as carrier for foreign epitopes,” Adv. Virus Res. 50:141-182, Academic Press (1998).Applicant
• Vicari, A.P., et aI., “Antitumor Effects of the Mouse Chemokine 6Ckine/SLC Through Angiostatic and Immunological Mechanisms,” J. Immunol. 165:1992-2000, The American Association of Immunologists (Aug. 2000).Applicant
• Visintin, M. et aI., “Selection of antibodies for intracellular function using a two-hybrid in vivo system,” Proc. Natl. Acad. Sci. USA 96:11723-11728, National Academy Press (1999).Applicant
• Walse, B., et al., “Transferred nuclear Overhauser effect spectroscopy study of a peptide from the PapG pilus subunit bound by the Escherichia coli PapD chaperone,” FEBS Lett. 412:115-120, Elsevier Science B.V. (1997).Applicant
• Warnes, A., et al., “Expression of the measles virus nucleoprotein gene in Escherichia coli and assembly of nucleocapsid-like structures,” Gene 160:173-178, Elsevier Science B.V. (1995).Applicant
• Watson, E., et al., “Structure determination of the intact major sialylated oligosaccharide chains of recombinant human erythropoietin expressed in Chinese hamster ovary cells,” Glycobiology 4:221-237, Oxford University Press (1994).Applicant
• Wei, Y.Q., et al., “Immunotherapy of tumors with xenogeneic endothelial cells as a vaccine,” Nat. Med. 6:1150-1166, Nature Publishing Company (Oct. 2000).Applicant
• Witherell, G.M., and Uhlenbeck, O.C., “Specific RNA Binding by Qβ Coat Protein,” Biochemistry 28:71-76, American Chemical Society (1989).Applicant
• Wong, C.K., et aI., “Elevation of proinflammatory cytosine (IL-18, IL-17, IL-12) and Th2 cytokine (IL-4) concentrations in patients with systemic lupus erythematosus,” Lupus 9:589-593, Macmillan Publishers Ltd. (2000).Applicant
• Wu, Q., et al. “Reversal of Spontaneous Autoimmune Insulitis in Nonobese Diabetic Mice by Soluble Lymphotoxin Receptor,” J. Exp. Med. 193:1327-1332, The Rockefeller University Press (Jun. 2001).Applicant
• Wuttke, M., et al., “Structural Characterization of Human Recombinant and Bone-derived Bone Sialoprotein,” J. Biol. Chem. 276:36839-36848, The American Society for Biochemistry and Molecular Biology, Inc. (2001).Applicant
• Wynne, S.A., et al., “The Crystal Structure of the Human Hepatitis B Virus Capsid,” Mol. Cell 3:771-780, Cell Press (1999).Applicant
• Kiong, C., et al., “Sindbis Virus: An Efficient, Broad Host Range Vector for Gene Expression in Animal Cells,” Science 243:1188-1191, American Association for the Advancement of Science (1989).Applicant
• Yao, Z., et al., “Human IL-17: A Novel Cytokine Derived from T Cells,” J. Immunol. 155:5483-5486, The American Association of Immunologists (1995).Applicant
• Yao, Z., et al., “Molecular characterization of the human interleukin (IL)-17 receptor,” Cytokine 9:794-800, Academic Press, Ltd. (1997).Applicant
• Yone, K., et al., “Epitopic Regions for Antibodies against Tumor Necrosis Factor α,” J. Biol. Chem. 270:19509-19515, The American Society for Biochemistry and Molecular Biology, Inc. (1995).Applicant
• Yuan, T-T., et al., “Subtype-Independent Immature Secretion and Subtype-Dependent Replication Deficiency of a Highly Frequent, Naturally Occurring Mutation of Human Hepatitis B Virus Core Antigen,” J. Virol. 73:10122-10128, American Society for Microbiology (1999).Applicant
• Zang, M., et al., “Production of Recombinant Proteins in Chinese Hamster Ovary Cells Using A Protein-Free Cell Culture Medium,” Bio/Technology 13:389-392, Nature Publishing Company (1995).Applicant
• Zhou, S., and Standring, D.N., “Cys Residues of the Hepatitis B Virus Capsid Protein Are Not Essential for the Assembly of Viral Core Particles but Can Influence Their Stability,” J. Virol. 66:5393-5398, American Society for Microbiology (1992).Applicant
• Zimmermann, N., et al., “Murine Eotaxin-2: A Constitutive Eosinophil Chemokine Induced by Allergen Challenge and IL-4 Overexpression,” J. Immunol. 165:5839-5846, The American Association of Immunologists (Nov. 2000).Applicant
• Ziolkowska, M., et al., “High Levels of IL-17 in Rheumatoid Arthritis Patients: IL-15 Triggers In Vitro IL-17 Production Via Cyclosporin A-Sensitive Mechanism,” J. Immunol. 164:2832-2838, The American Association of Immunologists (Mar. 2000).Applicant
• Zuercher, A.W., et al., “Oral anti-IgE immunization with epitope-displaying phage,” Eur. J. Immunol. 30:128-135, Wiley-Vch Verlag GmbH (Jan. 2000).Applicant
• Fehr, T., et al., “T cell-independent type I antibody response against B cell epitopes expressed repetitively on recombinant virus particles,” Proc. Natl. Acad. Sci. USA 95:9477-9481, National Academy Press (1998).Applicant
• Frenkel, D., et al., “Generation of auto-antibodies towards Alzheimer's disease vaccination,” Vaccine 19:2615-2619, Elsevier Science, Ltd. (Mar. 2001).Applicant
• International Search Report for International Application No. PCT/IB02/00166 mailed on Oct. 29, 2002. European Patent Office, Netherlands (2002).Applicant
• International Search Report for International Application No. PCT/IB02/00168 mailed on Nov. 4, 2002. European Patent Office, Netherlands (2002).Applicant
• Kozlovska, T.M., et al., “RNA Phage Qβ Coat Protein as a Carrier for Foreign Epitopes,” Intervirology 39:9-15, S. Karger AG (1996).Applicant
• Kratz, P.A., et al., “Native display of complete foreign protein domains on the surface of hepatitis B virus capsids,” Proc. Natl. Acad. Sci. USA 96:1915-1920, National Academy of Sciences (1999).Applicant
• Nieland, J.D., et al., “Chimeric Papillomavirus Virus-like Particles Induce a Murine Self-Antigen-Specific Protective and Therapeutic Antitumor Immune Response,” J. Cell. Biochem. 73:145-152, Wiley-Liss, Inc. (1999).Applicant
• Slepushkin, V.A., et al., “Protection of mice against influenza A virus challenge by vaccination with baculovirus-expressed M2 protein,” Vaccine 13:1399-1402, Elsevier Science Ltd. (1995).Applicant
• Vasiljeva, I., et al., “Mosaic Qβ coats as a new presentation model,” FEBS Lett. 431:7-11, Federation of European Biochemical Societies (1998).Applicant
• International Search Report for International Application No. PCT/IB 02/00166, mailed Jan. 31, 2003. European Patent Office, Netherlands (2002).Applicant
• Baba, T.W., et al., “Pathogenicity of Live, Attenuated SIV After Mucosal Infection of Neonatal Macaques,” Science 267:1820-1825, American Association for the Advancement of Science (1995).Applicant
• Bachmann, M.F., et al., “Dendritic cells process exogenous viral proteins and virus-like particles for class I presentation to CD8+ cytotoxic T lymphocytes,” Eur. J. Immunol. 26:2595-2600, VCH Verlagsgesellschaft mbH (1996).Applicant
• Boorsma, M., et al., “A temperature-regulated replicon-based DNA expression system,” Nat. Biotechnol. 18:429-432, Nature America, Inc. (Apr. 2000).Applicant
• Borisova, G., et al., “Hybrid Hepatitis B Virus Nucleocapsid Bearing an Immunodominant Region from Hepatitis B Virus Surface Antigen,” J. Virol. 67:3696-3701, American Society for Microbiology (1993).Applicant
• Cesareni, G., “Peptide display on filamentous phage capsids: A new powerful tool to study protein-ligand interaction,” FEBS Lett. 307:66-70, Elsevier Science Publishers B.V. (1992).Applicant
• Connor, R.I., et al., “lmmunological and Virological Analyses of Persons Infected by Human Immunodeficiency Virus Type 1 while Participating in Trials of Recombinant gp12O Subunit Vaccines,” J. Virol. 72:1552-1576, American Society for Microbiology (1998).Applicant
• Crameri, R. and Suter, M., “Display of biologically active proteins on the surface of filamentous phages: a cDNA cloning system for selection of functional gene products linked to the genetic information responsible for their production,” Gene 137:69-75, Elsevier Science Publishers B.V. (1993).Applicant
• Daniel. M.D., et al., “Protective Effects of a Live Attenuated SIV Vaccine with a Deletion in the nef Gene,” Science 258:1938-1941, American Association for the Advancement of Science (1992).Applicant
• de la Cruz, V.F., et al., “Immunogenicity and Epitope Mapping of Foreign Sequences via Genetically Engineered Filamentous Phage,” J. Biol. Chem. 263:4318-4322, The American Society for Biochemistry and Molecular Biology, Inc. (1988).Applicant
• Donnelly, J.J., et aI., “DNA Vaccines,” Annu. Rev. Immunol. 15:617-648, Annual Reviews, Inc. (1997).Applicant
• Ebina, S., et al., “Chemical Modification of Bovine Pancreatic Trypsin Inhibitor for Single Site Coupling of Immunogenic Peptides for NMR Conformational Analysis,” J. Biol. Chem. 264:7882-7888, The American Society for Biochemistry and Molecular Biology, Inc. (1989).Applicant
• Esposito, G., et al., “Conformational study of a short Pertussis toxin T cell epitope incorporated in a multiple antigen peptide template by CD and two-dimensional NMR: Analysis of the structural effects on the activity of synthetic immunogens,” Eur. J. Biochem. 217:171-187, Blackwell Science Ltd. on behalf of the Federation of European Biochemical Societies (1993).Applicant
• Förster, E., et al., “Natural and recombinant enzymatically active or inactive bee venom phospholipase A2 has the same potency to release histamine from basophils in patients with Hymenoptera allergy,” J. Allergy Clin. Immunol. 95:1229-1235, Mosby-Year Book, Inc. (1995).Applicant
• Frolov, I., et al., “Alphavirus-based expression vectors: Strategies and applications,” Proc. NatI. Acad. Sci. USA 93:11371-11377, National Academy Press (1996).Applicant
• Gilbert, S.C., et al., “A protein particle vaccine containing multiple malaria epitopes,” Nat. Biotechnol. 15:1280-1284, Nature America Publishing (1997).Applicant
• Greenstone, H.L., et al., “Chimeric paillomavirus virus-like particles elicit antitumor immunity against the E7 oncoprotein in an HPV16 tumor model,” Proc. Natl. Acad. Sci. USA 95:1800-1805, National Academy Press (1998).Applicant
• Hahn, C.S., et aI., “Infectious Sindbis virus transient expression vectors for studying antigen processing and presentation,” Proc. Natl. Acad. Sci. USA 89:2679-2683, National Academy Press (1992).Applicant
• Harding, C.V., and Song, R., “Phagocytic Processing of Exogenous Particulate Antigens by Macrophages for Presentation by Class I MHC Molecules,” J. Immunol. 153:4925-4933, The American Association of Irnmunologists (1994).Applicant
• Hilleman, M.R., “Six decades of vaccine development—a personal history,” Nat. Med. Vaccine Suppl. 4:507-514 (May 1998).Applicant
• Hui, E. K-W. et al., “Hepatitis B viral core proteins with an N-terminal extension can assemble into core-like particles but cannot be enveloped,” J. Gen. ViroI. 80:2647-2659, Society for General Microbiology (1999).Applicant
• lannolo, G., et al., “Construction, Exploitation and Evolution of a New Peptide Library Displayed at High Density by Fusion to the Major Coat Protein of Filamentous Phage,” Biol. Chem. 378:517-521, Walter de Gruyter & Co. (1997).Applicant
• lannolo, G., et al., “Modifying Filamentous Phage Capsid: Limits in the Size of the Major Capsid Protein,” J. Mol. Biol. 248:835-844, Academic Press, Ltd. (1995).Applicant
• Ikram, H., and Prince, A.M., “A method for coupling the Hepatitis B surface antigen to aldehyde-fixed erythrocytes for use in passive hemagglutination,” J. Virol. Methods 2:269-275, Elsevier/North-Holland Biomedical Press (1981).Applicant
• Kovacsovics-Bankowski, M., et al., “Efficient major histocompatibility complex class I presentation of exogenous antigen upon phagocytosis by macrophages,” Proc. Natl. Acad. Sci. USA 90:4942-4946, National Academy Press (1993).Applicant
• Lo, K. K-W., et al., “Surface-modified mutants of cytochrome P450cam: enzymatic properties and electrochemistry,” FEBS Lett. 451:342-346, Elsevier Science B.V. on behalf of the Federation of European Biochemical Societies (1999).Applicant
• Minenkova, O.O., et al., “Design of specific immunogens using filamentous phage as the carrier,” Gene 128:85-88, Elsevier Science Publishers B.V. (1993).Applicant
• Neurath, A.R., et al., “Hepatitis B Virus surface antigen (HBsAg) as carrier for synthetic peptides having an attached hydrophobic tail,” Mol. Immunol. 26:53-62, Pergamon Press (1989).Applicant
• Perham, R.N., et aI., “Engineering a peptide epitope display system on filamentous bacteriophage,” FEMS Microbiol. Rev. 17:25-31, Elsevier Science Publishers on behalf of the Federation of European Microbiological Societies (1995).Applicant
• Petrenko, V.A., et al., “A library of organic landscapes on filamentous phage,” Protein Engin. 9:797-801, Oxford University Press (1996).Applicant
• Pumpens, P. and Grens, E., “Hepatitis B core particles as a universal display model: a structure-function basis for development,” FEBS Lett. 442:1-6, Elsevier Science B.V. on behalf of the Federation of European Biochemical Societies (1999).Applicant
• Quash, G., et al., “The preparation of latex particles with covalently bound polyamines IgG and measles agglutinins and their use in visual agglutination tests,” J. Immunol. Methods 22:165-174, Elsevier/North-Holland Biomedical Press (1978).Applicant
• Raychaudhuri, S., and Rock, K.L., “Fully mobilizing host defense: Building better vaccines,” Nat. Biotechnol. 16:1025-1031, Nature America, Inc. (1998).Applicant
• Redfield, R.R., et al., “Disseminated vaccinia in a military recruit with Human Immunodeficiency Virus (HIV) disease,” N. Eng. J. Med. 316:673-676, Massachusetts Medical Society (1987).Applicant
• Rudolf, M.P., et al., Molecular Basis for Nonanaphylactogenicty of a Monoclonal Anti-IgE Antibody, J. Immunol. 165:813-819, The American Association of Immunologists (2000).Applicant
• Sedlik, C., et al., “Recombinant parvovirus-like particles as an antigen carrier: A novel nonreplicative exogenous antigen to elicit protective antiviral cytotoxic T cells,” Proc. Natl. Acad. Sci. USA 94:7503-7508, National Academy Press (1997).Applicant
• Shen, L., et al., “Recombinant Virus Vaccine-Induced SIV-Specific CD8♦ Cytotoxic T Lymphocytes,” Science 252:440-443, American Association for the Advancement of Science (1991).Applicant
• Tanimori, H., et al., “Enzyme Immunoassay of Neocarzinostatin Using β-Galactosidase as Label,” J. Pharm. Dyn. 4:812-819, Pharmaceutical Society of Japan (1981).Applicant
• Townsend, A., and Bodmer, H., “Antigen recognition by class I-restricted T lymphocytes,” Ann. Rev. Immunol. 7:601-624, Annual Reviews, Inc. (1989).Applicant
• VanCott, T.C., et al., “Antibodies with Specificity to Native gp12O and Neutralization Activity against Primary Human Immunodeficiency Virus Type 1 Isolates Elicited by Immunization with Oligomeric gp16O,” J. Virol. 71:4319-4330, American Society for Microbiology (1997).Applicant
• Watkins, S.J., et al., “The ‘adenobody’ approach to viral targeting: specific and enhanced adenoviral gene delivery,” Gene Ther. 4:1004-1012, Stockton Press (1997).Applicant
• Willis, A.E., et al., “Immunological properties of foreign peptides in multiple display on a filamentous bacteriophage,” Gene 128:79-83, Elsevier Science Publishers B.V. (1993).Applicant
• Dialog File 351, Accession No. 9831660, Derwent WPI English language abstract for WO 94/06472 (Document AP3).Applicant
• International Preliminary Examination Report for International Application No. PCT/IB99/01925, European Patent Office, Munich (Aug. 2000) (not for publication).Applicant
• International Search Report for International Application No. PCT/IB99/01925, European Patent Office, Netherlands (Jun. 2000) (not for publication).Applicant
• NCBI Entrez, GenBank Report, Accession No. P03153, from Seeger, C., et al. (Jan. 1990).Applicant
• NCBI Entrez, GenBank Report, Accession No. X59397, from Jordan, C.T., et al. (Nov. 1991).Applicant
• NCBI Entrez, GenBank Report, Accession No. 711678A, from Shipolini, R.A., et al. (Jul. 1992).Applicant
• NCBI Entrez, GenBank Report, Accession No. M27603, from Orndorff, P.E., and Falkow, S. (Apr. 1993).Applicant
• NCBI Entrez, GenBank Report, Accession No. M207O6, from Nassal M. (Apr. 1993).Applicant
• NCBI Entrez, GenBank Report, Accession No. AAA37490, from Rouvier E. (Jul. 1993).Applicant
• NCBI Entrez, GenBank Report, Accession No. M90520, from Kew, M.C., et al. (Aug. 1993).Applicant
• NCBI Entrez, GenBank Report, Accession No. X00981, from Klemm, P. (Sep. 1993).Applicant
• NCBI Entrez, GenBank Report, Accession No. VCBPQB, from Maita, T., and Konigsberg, W. (Dec. 1993).Applicant
• NCBI Entrez, GenBank Report, Accession No. AAA16663, from Kozlovska, T.M., et al. (Mar. 1994).Applicant
• NCBI Entrez, GenBank Report, Accession No. X02514, from Yanisch-Perron, C., et al. (May 1994).Applicant
• NCBI Entrez, GenBank Report, Accession No. X85256, from Lai, M.E., et al. (Apr. 1995).Applicant
• NCBI Entrez, GenBank Report, Accession No. X85259, from Lai, M.E., et al., (Apr. 1995).Applicant
• NCBI Entrez, GenBank Report, Accession No. X85260, from Lai, M.E., et al. (Apr. 1995).Applicant
• NCBI Entrez, GenBank Report, Accession No. X85272, from Lai, M.E., et al. (Apr. 1995).Applicant
• NCBI Entrez, GenBank Report, Accession No. X85275, from Lai, M.E., et al. (Apr. 1995).Applicant
• NCBI Entrez, GenBank Report, Accession No. X85284, from Lai, M.E., et al. (Apr. 1995).Applicant
• NCBI Entrez, GenBank Report, Accession No. X85285, from Lai, M.E., et al. (Apr. 1995).Applicant
• NCBI Entrez, GenBank Report, Accession No. X85286, from Lai, M.E., et al. (Apr. 1995).Applicant
• NCBI Entrez, GenBank Report, Accession No. X85287, from Lai, M.E., et al. (Apr. 1995).Applicant
• NCBI Entrez, GenBank Report, Accession No. X85291, from Lai, M.E., et al. (Apr. 1995).Applicant
• NCBI Entrez, GenBank Report, Accession No. X85293, from Lai, M.E., et al. (Apr. 1995).Applicant
• NCBI Entrez, GenBank Report, Accession No. X85295, from Lai, M.E., et al. (Apr. 1995).Applicant
• NCBI Entrez, GenBank Report, Accession No. X85296, from Lai, M.E., et al. (Apr. 1995).Applicant
• NCBI Entrez, GenBank Report, Accession No. X85297, from Lai, M.E., et al. (Apr. 1995).Applicant
• NCBI Entrez, GenBank Report, Accession No. X85298, from Lai, M.E., et al. (Apr. 1995).Applicant
• NCBI Entrez, GenBank Report, Accession No. X85299, from Lai, M.E., et al. (Apr. 1995).Applicant
• NCBI Entrez, GenBank Report, Accession No. X85301, from Lai, M.E., et al. (Apr. 1995).Applicant
• NCBI Entrez, GenBank Report, Accession No. X85302, from Lai, M.E., et al. (Apr. 1995).Applicant
• NCBI Entrez, GenBank Report, Accession No. X85303, from Lai, M.E., et al. (Apr. 1995).Applicant
• NCBI Entrez, GenBank Report, Accession No. X85305, from Lai, M.E., et al. (Apr. 1995).Applicant
• NCBI Entrez, GenBank Report, Accession No. X85307, from Lai, M.E., et al. (Apr. 1995).Applicant
• NCBI Entrez, GenBank Report, Accession No. X85311, from Lai, M.E., et al. (Apr. 1995).Applicant
• NCBI Entrez, GenBank Report, Accession No. X85314, from Lai, M.E., et al. (Apr. 1995).Applicant
• NCBI Entrez, GenBank Report, Accession No. X85315, from Lai, M.E., et al. (Apr. 1995).Applicant
• NCBI Entrez, GenBank Report, Accession No. X85316, from Lai, M.E., et al. (Apr. 1995).Applicant
• NCBI Entrez, GenBank Report, Accession No. X85317, from Lai, M.E., et al. (Apr. 1995).Applicant
• NCBI Entrez, GenBank Report, Accession No. X85319, from Lai, M.E, et al. (Apr. 1995).Applicant
• NCBI Entrez, GenBank Report, Accession No. X80925, from Karayiannis, P. (Dec. 1995).Applicant
• NCBI Entrez, GenBank Report, Accession No. AAC50341, from Yao, Z., et aI. (Jan. 1996).Applicant
• NCBI Entrez, GenBank Report, Accession No. X72702, from Preisler-Adams, S., et al. (Feb. 1996).Applicant
• NCBI Entrez, GenBank Report, Accession No. VCBPR7, from Weber, K., et al. (Apr. 1996).Applicant
• NCBI Entrez, GenBank Report, Accession No. 1604193A, from Gomez, F., et al. (Oct. 1996).Applicant
• NCBI Entrez, GenBank Report, Accession No. B56338, from Hoffman, D.R. (May 1997).Applicant
• NCBI Entrez, GenBank Report, Accession No. U95551, from Rao, B.S., et al. (Jun. 1997).Applicant
• NCBI Entrez, GenBank Report, Accession No. S14764, from Vandermeers, A., et al. (Oct. 1997).Applicant
• NCBI Entrez, GenBank Report, Accession No. P03611, from Weber, K., et al. (Nov. 1997).Applicant
• NCBI Entrez, GenBank Report, Accession No. AAC14699, from Beekwilder, M.J., et al. (Apr. 1998).Applicant
• NCBI Entrez, GenBank Report, Accession No. AAC14704, from Beekwilder, M.J., et aI. (Apr. 1998).Applicant
• NCBI Entrez, GenBank Report, Accession No. AF043593, from Gunther, S., et al. (May 1998).Applicant
• NCBI Entrez, GenBank Report, Accession No. 1POC, from Scott, D.L., et aI. (Sep. 1998).Applicant
• NCBI Entrez, GenBank Report, Accession No. CAA30374, from Inokuchi, Y., et al. (Feb. 1999).Applicant
• NCBI Entrez, GenBank Report, Accession No. X02496, from Bichko, V., et al. (Apr. 1999).Applicant
• NCBI Entrez, GenBank Report, Accession No. MFIV62, from Cox, N.J., et al. (Jul. 1999).Applicant
• NCBI Entrez, GenBank Report, Accession No. VCBPFR, from Wittmann-Liebold, B., at al. (Jul. 1999).Applicant
• NCBI Entrez, GenBank Report, Accession No. A59055, from Hoffman, D.R., and Schmidt, J.O. (Aug. 1999).Applicant
• NCBI Entrez, GenBank Report, Accession No. B59055, from Hoffman, D.R., and Schmidt, J.O. (Aug. 1999).Applicant
• NCBI Entrez, GenBank Report, Accession No. AF051814, from Boyd, E.F., and Hartl, D.L. (Sep. 1999).Applicant
• NCBI Entrez, GenBank Report, Accession No. AF051815, from Boyd, E.F., and Hartl, D.L. (Sep. 1999).Applicant
• NCBI Entrez, GenBank Report, Accession No. AF110999, from Chang, S.F., et al. (Oct. 1999).Applicant
• NCBI Entrez, GenBank Report, Accession No. AB033559, from Okamoto, H., et al. (Oct. 1999).Applicant
• NCBI Entrez, GenBank Report, Accession No. AB010289, from Koseki, T., et al. (Dec. 1999).Applicant
• NCBI Entrez, GenBank Report, Accession No. AJ132364, from Graupner, S., et al. (Apr. 2000).Applicant
• NCBI Entrez, GenBank Report, Accession No. AF237482, from Johnson, J.R., et al. (May 2000).Applicant
• NCBI Entrez, GenBank Report, Accession No. M32138, from Tong, S.P., et al. (Jul. 2000).Applicant
• NCBI Entrez, GenBank Report, Accession No. AF229646, from Skerker, J.M., and Shapiro, L. (Aug. 2000).Applicant
• NCBI Entrez, GenBank Report, Accession No. M95589, from Shi, H., et al. (Jan. 2001).Applicant
• NCBI Entrez, GenBank Report, Accession No. VCBPM2, from Min Jou, W.. et al. (Jan. 2001).Applicant
• NCBI Entrez, GenBank Report, Accession No. AF323080, from Steppan, C.M., et al. (Jan. 2001).Applicant
• NCBI Entrez, GenBank Report, Accession No. AF323081, from Steppan, C.M., et al. (Jan. 2001).Applicant
• NCBI Entrez, GenBank Report, Accession No. U14003, from Plunkett, G., III, et al. (Jan. 2001).Applicant
• NCBI Entrez, GenBank Report, Accession No. AF121239, from Hannoun, C., et al. (Feb. 2001).Applicant
• NCBI Entrez, GenBank Report, Accession No. AF121240, from Hannoun, C., et al. (Feb. 2001).Applicant
• NCBI Entrez, GenBank Report, Accession No. AF121242, from Hannoun, C., et al. (Feb. 2001).Applicant
• NCBI Entrez, GenBank Report, Accession No. X59795, from Lai, M.E., et al. (Mar. 2001).Applicant
• NCBI Entrez, GenBank Report, Accession No. X65257, from Lai, M.E., et al. (Mar. 2001).Applicant
• NCBI Entrez, GenBank Report, Accession No. X65258, from Lai, M.E., et al. (Mar. 2001).Applicant
• NCBI Entrez, GenBank Report, Accession No. AF151735, from Gerner, P., et al. (Apr. 2001).Applicant
• NCBI Entrez, GenBank Report, Accession No. AJ000636, from Gousset, N., et al. (Nov. 2001).Applicant
• NCBI Entrez, GenBank Report, Accession No. AAB59424, from Kenten, J.H., et al. (Feb. 2002).Applicant
• NCBI Entrez, GenBank Report, Accession No. AAC06250, from Beekwilder, M.J., et al. (Mar. 2002).Applicant
• NCBI Entrez, GenBank Report, Accession No. L09137, from Yanisch-Perron, C., et al. (May 2002).Applicant
• NCBI Entrez, GenBank Report, Accession No. 009006, from Hromas, R., et al. (Jun. 2002).Applicant
• NCBI Entrez, GenBank Report, Accession No. 940224, from Nagasawa, T., et al. (Jun. 2002).Applicant
• NCBI Entrez, GenBank Report, Accession No. P34884, from Bernhagen, J., et al. (Jun. 2002).Applicant
• NCBI Entrez, GenBank Report, Accession No. P06821, from Winter, G., et aI. (Jun. 2002).Applicant
• NCBI Entrez, GenBank Report, Accession No. P30904, from Sakai, M., et al. (Jun. 2002).Applicant
• NCBI Entrez, GenBank Report, Accession No. NP_040754, from Inokuchi, Y., et al. (Jun. 2003).Applicant
• NCBI Entrez, GenBank Report, Accession No. NP_061354, from Ishikawa, S., et al. (Sep. 2003).Applicant
• NCBI Entrez, GenBank Report, Accession No. NP_031804, from Lenda, D.M., et al. (Sep. 2003).Applicant
• NCBI Entrez, GenBank Report, Accession No. NP_006410, from Luther, S.A., et al. (Sep. 2003).Applicant
• NCBI Entrez, GenBank Report, Accession No. NP_000748, from Yao, G.Q., et al. (Sep. 2003).Applicant
• NCBI Entrez, GenBank Report Accession No. P03069, from Hinnebusch, A.G., et al. (Sep. 2003).Applicant
• NCBI Entrez, GenBank Report, Accession No. 000585, from Hromas, R., et al. (Sep. 2003).Applicant
• NCBI Entrez, GenBank Report, Accession No. P14174, from Weiser, W.Y., et aI. (Sep. 2003).Applicant
• NCBI Entrez, GenBank Report, Accession No. P48061, from Spotila, L.D., et aI. (Sep. 2003).Applicant
• NCBI Entrez, GenBank Report, Accession No. P80003, from Vandermeers, A., et al. (Sep. 2003).Applicant
• Swiss-Prot/TrEMBL, TN11_Mouse, Primary Accession No. O35235, entered in Swiss-Prot in Oct. 2001.Applicant
• Swiss-Prot/TrEMBL, TN11_Human, Primary Accession No. O14788, entered in Swiss-Prot in Oct. 2001.Applicant
• Co-pending U.S. Appl. No. 10/264,267, inventors Bachmann, M., filed Oct. 4, 2002 (Not Published).Applicant
• Co-pending U.S. Appl. No. 10/289,456, inventors Bachmann et aI., filed Nov. 7, 2002 (Not Published).Applicant
• Co-pending U.S. Appl. No. 10/617,876, inventors Bachmann et al., filed Jul. 14, 2003 (Not Published).Applicant
• Co-pending U.S. Appl. No. 10/346,190, inventors Bachmann et al., filed Jan. 17, 2003 (Not Published).Applicant
• Co-pending U.S. Appl. No. 10/622,087, inventors Bachmann et al., filed Jul. 18, 2003 (Not Published).Applicant
• Co-pending U.S. Appl. No. 10/622,124, inventors Bachmann et al., filed Jul. 18, 2003 (Not Published).Applicant
• Milich, D.R., et al., “The Hepatitis B Virus Core and e Antigens Elicit Different Th Cell Subsets: Antigen Structure Can Affect Th Cell Phenotype,” J. Virol. 71:2192-2201, American Society for Microbiology (1997).Applicant
• Milich, D.R., et al., “The Hepatitis Nucleocapsid as a Vaccine Carrier Moiety,” Ann. N.Y. Acad. Sci. 754:187-201, New York Academy of Sciences (1995).Applicant
• “Annex to Form PCT/ISA/206. Communication Relating to the Results of the Partial International Search for PCT/EP03/07850,” 3 pages, European Patent Office, The Netherlands (mailed Nov. 6, 2003).Applicant
• International Search Report for International Application No. PCT/EP03/07850, mailed Nov. 11, 2003, International Search Authority, European Patent Office, The Netherlands.Applicant
• Curtiss, L. K., et al., “The relative immunodominance of haptenic determinants on a complex hapten phage conjugate,” Immunochemisty 12:949-957, Pergamon Press, Great Britain (Dec. 1975).Applicant
• Lechner, F., et al., “Virus-like particles as a modular system for novel vaccines,” Intervirology 45:212-217, S. Karger AG, Basel (Jul.-Dec. 2002).Applicant
• Pumpens P., et al., “Evaluation of HBs, HBc, and frCP virus-like particles for expression of human papillomavirus 16 E7 oncoprotein epitopes,” Intervirology 45:24-32, S. Karger AG, Basel (Jan. 2002).Applicant
• Nieland, J.D., et al., “Chimeric papillomavirus virus-like particles induce a murine self-antigen-specific protective and therapeutic arititumor immune response,” J. Cell. Biochem. 73:145-152, Wiley-Liss Inc. (1999).Applicant
• Dialog File 351, Accession No. 1994-111516, unverified Derwent WPI English language abstract for FR2695563.Applicant
• International Search Report for International Application No. PCT/IB01/00741, mailed Mar. 5, 2002, International Searching Authority European Patent Office, Netherlands.Applicant
• International Search Report for International Application No. PCT/IB02/00166, mailed Jan. 31, 2003, International Searching Authority, European Patent Office, Netherlands.Applicant
• Office Action mailed Jun. 6, 2001, for United States Patent Application No. 09/449,631, Rennet et al., filed Nov. 30, 1999. (Not For Publication).Applicant
• Office Action mailed Feb. 27, 2002, for U.S. Appl. No. 09/449,631, Renner et al., filed Nov. 30, 1999. (Not For Publication).Applicant
• Office Action mailed Nov. 14, 2002, for U.S. Appl. No. 09/449,631, Renner et al., filed Nov. 30, 1999. (Not For Publication).Applicant
• Office Action mailed Mar. 1, 2004, for U.S. Appl. No. 10/050,902, Renner et al., filed Jan. 18, 2002. (Not For Publication).Applicant
• Print out of Xenova Group PLC web page, www.xenova.co.uk/t.addiction.html; accessed Oct. 8, 2004.Applicant
• Print Out of Xenova Group PLC web page, www.xenova.co.uk/dc_ta_nic.html; accessed Oct. 8, 2004.Applicant
• Print out of Xenova Group PLC web page, www.xenova.co.uk/dc_ta_cd.html; accessed Oct. 8, 2004.Applicant
• Press release by Xenova Group PLC, accessed at www.xenova.co.uk/PressReleases/pr_20040614_01.html; Jun. 14, 2004.Applicant
• Press release by Xenova Group PLC, accessed at www.xenova.co.uk/PressReleases/pr_20040714_01.htmI; Jul. 14, 2004.Applicant